Document_and_Entity_Informatio
Document and Entity Information (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Apr. 09, 2015 | |
Document and Entity Information: | ||
Entity Registrant Name | AXIM BIOTECHNOLOGIES, INC. | |
Entity Trading Symbol | AXIM | |
Document Type | 10-K | |
Document Period End Date | 31-Dec-14 | |
Amendment Flag | FALSE | |
Entity Central Index Key | 1514946 | |
Current Fiscal Year End Date | -19 | |
Entity Common Stock, Shares Outstanding | 34,018,000 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Well-known Seasoned Issuer | No | |
Document Fiscal Year Focus | 2014 | |
Document Fiscal Period Focus | FY | |
Entity Public Float | $330,000,000 |
Consolidated_Balance_Sheets
Consolidated Balance Sheets (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Current assets: | ||
Cash | $661,128 | $127 |
Prepaid expenses | 72,329 | |
Loan receivable | 5,000 | 3,000 |
Total current assets | 738,457 | 3,127 |
Other Assets: | ||
Intangible asset - Licenses, net | 53,696 | |
Total other assets | 53,696 | |
TOTAL ASSETS | 738,457 | 56,823 |
Current liabilities: | ||
Accounts payable and accrued liabilities | 144,385 | 52,988 |
Due to shareholder | 5,000 | 45,002 |
Convertible shareholder loan | 50,000 | |
Convertible loan | 50,000 | |
Royalty fees payable | 2,750 | |
Due to first insurance funding | 54,020 | |
Due to related party | 65,775 | |
Promissory note - related party | 1,000,000 | |
Total current liabilities | 1,319,180 | 150,740 |
STOCKHOLDERS' DEFICIT | ||
Preferred stock, $0.0001 par value, 5,000,000 shares authorized; 1,000,000 issued and outstanding | 100 | 100 |
Common stock, $0.0001 par value, 300,000,000 and 195,000,000 shares authorized, respectively; 33,000,000 issued and outstanding | 3,300 | 3,300 |
Additional paid in capital | 107,841 | 11,700 |
Accumulated deficit | -691,964 | -109,017 |
TOTAL STOCKHOLDERS' DEFICIT | -580,723 | -93,917 |
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $738,457 | $56,823 |
Consolidated_Balance_Sheets_Pa
Consolidated Balance Sheets Parentheticals (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Parentheticals | ||
Preferred Stock, par value | $0.00 | $0.00 |
Preferred Stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred Stock, shares issued | 1,000,000 | 1,000,000 |
Preferred Stock, shares outstanding | 1,000,000 | 1,000,000 |
Common Stock, par value | $0.00 | $0.00 |
Common Stock, shares authorized | 300,000,000 | 195,000,000 |
Common Stock, shares issued | 33,000,000 | 33,000,000 |
Common Stock, shares outstanding | 33,000,000 | 33,000,000 |
Consolidated_Statement_of_Oper
Consolidated Statement of Operations (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Expenses: | ||
Total operating expenses | $505,729 | $62,886 |
Loss from operations | ($505,729) | ($62,886) |
Other Income and Expense: | 32,522 | |
Interest expense | 32,522 | |
loss from Continuing operation before provision of income tax | -538,251 | -62,886 |
Provision for income taxes | 0 | |
LOSS FROM CONTINUING OPERATION | -538,251 | -62,886 |
LOSS FROM DISCONTINUED OPERATION | -44,696 | -26,333 |
NET LOSS | ($582,947) | ($89,219) |
Loss per common share from continuing operation- basic and diluted | ($0.02) | $0 |
Loss per common share from discontinued operation- basic and diluted | $0 | $0 |
Loss per common share - basic and diluted | ($0.02) | $0 |
Weighted average common shares outstanding - basic and diluted | 33,000,000 | 33,000,000 |
Consolidated_Statement_of_Stoc
Consolidated Statement of Stockholders' Deficit (USD $) | Common Stock Shares | Common Stock Amount | Preferred Stock Shares | Preferred Stock Amount | Additional Paid In Capital | Accumulated Deficit | Total |
USD ($) | USD ($) | USD ($) | |||||
Balance at Dec. 31, 2012 | 33,000,000 | 3,300 | 1,000,000 | 100 | 11,700 | -19,798 | -4,698 |
Net Loss-2013 | ($89,219) | ($89,219) | |||||
Balance at Dec. 31, 2013 | 33,000,000 | 3,300 | 1,000,000 | 100 | 11,700 | -109,017 | -93,917 |
Forgiveness of debt | 96,141 | 96,141 | |||||
Net Loss-2014 | ($582,947) | ($582,947) | |||||
Balance at Dec. 31, 2014 | 33,000,000 | 3,300 | 1,000,000 | 100 | 107,841 | -691,964 | -580,723 |
Consolidated_Statements_of_Cas
Consolidated Statements of Cash Flows (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net (loss) | ($582,947) | ($89,219) |
Loss from discontinued operation | 44,696 | 26,333 |
Loss from continuing operation | -538,251 | -62,886 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Expenses incurred by related party on behalf of Company | 65,775 | |
Change in operating assets and liabilities: | ||
License fee receivable | -4,000 | 9,000 |
Accounts payable and accrued expenses | 145,786 | 20,418 |
Prepaid expenses | -72,329 | |
Change in due to first insurance funding | 54,020 | |
Royalty fee payable | 450 | |
Deferred revenue | -21,667 | |
NET CASH USED IN OPERATING ACTIVITIES OF CONTINUING OPERATION | -348,999 | -54,685 |
NET CASH PROVIDED BY OPERATING ACTIVITIES OF DISCONTINUED OPERATION | 10,000 | 21,667 |
NET CASH USED IN OPERATING ACTIVITIES | -338,999 | -33,018 |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
NET CASH USED IN INVESTING ACTIVITIES OF CONTINUING OPERATION | 0 | |
NET CASH USED IN INVESTING ACTIVITIES | 0 | |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Proceeds from shareholder loan | 14,017 | |
Advance - Sanammad Foundation, Inc. | -5,000 | |
Loan proceeds from shareholder | 5,000 | |
Proceeds from promissory note - related party | 1,000,000 | |
NET CASH PROVIDED BY FINANCING ACTIVITIES OF CONTINUING OPERATION | 1,000,000 | 14,017 |
NET CASH PROVIDED BY FINANCING ACTIVITIES OF DISCONTINUED OPERATION | 0 | |
NET CASH PROVIDED BY FINANCING ACTIVITIES | 1,000,000 | 14,017 |
NET CHANGE IN CASH | 661,001 | -19,001 |
CASH BALANCES | ||
Beginning of year | 127 | 19,128 |
End of year | 661,128 | 127 |
CASH PAID DURING THE YEAR FOR: | ||
Interest | 0 | |
Income taxes | 0 | |
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING TRANSACTIONS: | ||
Gain on settlement of debt transferred to additional paid in capital | 96141 | 0 |
Expenses paid by related party | $65,775 |
ORGANISATION
ORGANISATION | 12 Months Ended |
Dec. 31, 2014 | |
ORGANISATION | |
ORGANISATION | NOTE 1: ORGANIZATION |
The Company was originally incorporated in Nevada on November 18, 2010, as Axim International Inc. On July 24, 2014, the Company changed its name to AXIM Biotechnologies, Inc. to better reflect its business operations. The Company’s principal executive office is located at 18 East 50th Street, 5th Floor, New York, NY 10022. On August 7, 2014, the Company formed a wholly owned Nevada subsidiary named Axim Holdings, Inc. This subsidiary will be used to help facilitate the anticipated activities planned by the Company. | |
In early 2014, the Company discontinued its organic waste marketable by-product business to focus on its anticipated new business to become an innovative biotechnology company working on the treatment of pain, spasticity, anxiety and other medical disorders with the application of cannabinoids based products as well as focusing on research, development and production of pharmaceutical, nutriceutical and cosmetic products as well as procurement of genetically and nano-controlled active ingredients. | |
BASIS_OF_PRESENTATION
BASIS OF PRESENTATION | 12 Months Ended |
Dec. 31, 2014 | |
BASIS OF PRESENTATION: | |
BASIS OF PRESENTATION | NOTE 2: BASIS OF PRESENTATION: |
The audited consolidated financial statements of AXIM Biotechnologies, Inc. (formerly Axim International, Inc.) as of December 31, 2014 and 2013 have been prepared in accordance with United States generally accepted accounting principles (“US GAAP”). The Company has adopted ASU 2014-10, and as a result, these financials will no longer incorporate the wording “Development Stage Company”. Also, the “Since inception till date” column is no longer used. | |
On June 9, 2014, the board of directors of the Company adopted a resolution approving a certificate of amendment to the Company’s Articles of Incorporation to: (i) change the name of the Company to “AXIM Biotechnologies, Inc.;” and (ii) increase in the number of authorized shares of common stock of the Company from one hundred ninety five million (195,000,000) shares of common stock, par value $0.0001 per share, to three hundred million (300,000,000) shares of common stock, par value $0.0001 per share. |
SIGNIFICANT_ACCOUNTING_POLICIE
SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2014 | |
SIGNIFICANT ACCOUNTING POLICIES: | |
SIGNIFICANT ACCOUNTING POLICIES | NOTE 3: SIGNIFICANT ACCOUNTING POLICIES |
Use of estimates | |
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenue and expenses during reporting periods. Actual results could differ from these estimates. | |
Cash equivalents | |
The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. | |
Revenue Recognition | |
The Company recognizes revenue on four basic criteria that must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the fee charged for services rendered and products delivered and the collectability of those fees. Revenue is generally recognized upon shipment. | |
Revenue recognized during the year ended December 31, 2014 and 2013 related to sales of product of $10,000 and $21,667, respectively, which is included in loss from discontinued operations. | |
Principles of consolidation | |
The consolidated financial statements include the accounts of Axim Biotechnologies, Inc. and its wholly owned subsidiary Axim Holdings, Inc. as of December 31, 2014. All significant intercompany transactions and balances have been eliminated in consolidation. | |
Fair value of financial instruments | |
The Company follows paragraph 825-10-50-10 Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification ("Paragraph 820-10-35-37") to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value, and expands disclosures about fair value measurements. | |
Income taxes | |
The Company follows Section 740-10, Income tax (“ASC 740-10”) Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date. | |
The Company adopted section 740-10-25 of the FASB Accounting Standards Codification ("Section 740-10-25"). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25. | |
Net loss per common share | |
Net loss per common share is computed pursuant to section 260-10-45 Earnings Per Share (“ASC 260-10”) of the FASB Accounting Standards Codification. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be ant dilutive. | |
Recently issued accounting standards | |
In June of 2014 the Financial Accounting Standards Board issued Accounting Standards Update ASU 2014-10, “Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation” (“ASU 2014-10”). The amendments in ASU 2014-10 remove the definition of a development stage entity from the master glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. | |
In August, 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties About an Entities Ability to Continue as a Going Concern. The standard is intended to define management’s responsibility to decide whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The standard requires management to decide whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. The standard provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations in the footnotes. The standard becomes effective in the annual period ending after December 15, 2016, with early application permitted. The adoption of this pronouncement is not expected to have a material impact on the financial statements. Management’s evaluations regarding the events and conditions that raise substantial doubt regarding the Company’s ability to continue as a going concern have been disclosed in Note 7. | |
The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations. | |
The Company has elected to adopt the provisions of ASU 2014-10 for the current year ending December 31, 2014. The adoption of ASU 2014-10 did not have a significant impact on our results of operations, financial condition or cash flow. | |
Other recent accounting pronouncements issued by the FASB and the SEC did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements. | |
CHANGE_OF_CONTROL
CHANGE OF CONTROL | 12 Months Ended | |||
Dec. 31, 2014 | ||||
CHANGE OF CONTROL: | ||||
CHANGE OF CONTROL | NOTE 4: CHANGE OF CONTROL | |||
Two new owners purchased most of the Company common stock and all of the preferred stock on March 21, 2014. As a part of that sale specified receivables, payables and accrued expenses were consolidated and transferred to a third party. Because the “Debt Settlement Agreement” was a part of the stock transfer agreement the net assigned debt was credited to additional paid in capital. This was done with the consent of all creditors. | ||||
Settlement of debt at point of sale: | Amount | |||
Accounts payable | $ | -54,389 | ||
Royalty payable | -2,750 | |||
Shareholder loan | -45,002 | |||
Allowance for doubtful accounts | -9,000 | |||
License fee receivable | 15,000 | |||
Paid in capital | $ | 96,141 | ||
The convertible loan in the amount of $50,000 was not transferred and remains outstanding as of December 31, 2014. | ||||
PROMISSORY_NOTE_RELATED_PARTY
PROMISSORY NOTE - RELATED PARTY | 12 Months Ended | ||||
Dec. 31, 2014 | |||||
PROMISSORY NOTE - RELATED PARTY | |||||
PROMISSORY NOTE - RELATED PARTY | NOTE 5: PROMISSORY NOTE - RELATED PARTY | ||||
On August 8, 2014 the Company entered into a Promissory Note Agreement with CanChew Biotechnologies, LLC (CCB), a related party (the owners of CCB also own 90% of the outstanding shares of the Company), under which it borrowed $1,000,000 to fund working capital. The loan is a demand note which bears interest at a rate of 7% annually. | |||||
The following table summarizes promissory note payable as of December 31, 2014 and 2013: | |||||
December 31, | December 31, | ||||
2014 | 2013 | ||||
Promissory note payable, due on demand, interest at 7% | $ | 1,000,000 | $ | - | |
Accrued interest | 28,053 | - | |||
$ | 1,028,053 | $ | - | ||
The Company recognized interest expense of $28,053 and $0 for the years ended December 31, 2014 and 2013 respectively, included in Accounts payable and accrued liabilities. | |||||
RELATED_PARTY_TRANSACTIONS
RELATED PARTY TRANSACTIONS | 12 Months Ended |
Dec. 31, 2014 | |
RELATED PARTY TRANSACTIONS: | |
RELATED PARTY TRANSACTIONS | NOTE 6: RELATED PARTY TRANSACTIONS |
From inception to December 31, 2014, the Company ex-president advanced a total of $45,002 to fund working capital needs. That amount was settled as a part of the “Debt Settlement Agreement.” | |
Effective November 26, 2012, the Company entered into a separate Convertible Loan Agreement with its ex-President, under which it borrowed $50,000, in the form of a non-interest bearing note. In January 2015, this note was extended until June 30, 2015 under the same terms. The loan is convertible into common stock at $0.10 per share at the option of the lender any time after February 28, 2013. As of December 31, 2014 the loan has not been converted. The Company used the proceeds of this loan to fund the purchase of license rights under the November 26, 2012, agreement with Omega Research Corporation. During the year 2014, the Convertible Loan was transferred to a third party | |
On May 21, 2014, the Company President advanced an additional $5,000 to the Company to fund working capital needs. This brings the total amount due to shareholder to $55,000 as of December 31, 2014, including convertible loan. | |
On August 8, 2014, the Company entered into a Promissory Note Agreement with CanChew Biotechnologies, LLC (CCB), a related party (The owners of CCB also own 90% of the outstanding shares of the Company), under which it borrowed $1,000,000 to fund working capital. The loan is a demand note which bears interest at a rate of 7% annually. For the year ended December 31, 2014 the Company charged $28,053 as interest expenses to operation (refer note 5). | |
On June 25, 2014, the Company received a non interest bearing advance from CCB of $30,000 to pay the down payment on its D & O liability insurance. In addition the Company during the year 2014 was advanced an additional $35,775 for operating expenses principally for the owner’s salary. This advance is non-interest bearing and is due on demand. The total outstanding due to related party as of December 31, 2014 and 2013 is $65,775 and $0, respectively. | |
GOING_CONCERN
GOING CONCERN | 12 Months Ended |
Dec. 31, 2014 | |
GOING CONCERN: | |
GOING CONCERN | NOTE 7: GOING CONCERN |
The Company’s consolidated financial statements have been presented assuming that the Company will continue as a going concern. As shown in the consolidated financial statements, the Company has negative working capital of $580,723, has an accumulated deficit of $691,964, has cash used in operating activities of continuing operations $348,999 and presently does not have the resources to accomplish its objectives during the next twelve months. These conditions raise substantial doubt about the ability of the Company to continue as a going concern. The consolidated financial statements do not include any adjustments related to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue in operation. | |
The Company intends to raise additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. |
AMORTIZATION_AND_IMPAIRMENT
AMORTIZATION AND IMPAIRMENT | 12 Months Ended |
Dec. 31, 2014 | |
AMORTIZATION AND IMPAIRMENT | |
AMORTIZATION AND IMPAIRMENT | NOTE 8: AMORTIZATION AND IMPAIRMENT |
The Company has determined that it is more likely than not that the value of the licenses has diminished. There is no open market for this type of asset and no comparable assets have recently traded. Therefore, the Company reduced the value of its intangible asset to nil. The Company during the years ended December 31, 2014 and 2013, charged as impairment expense of $52,103 and $30,000, respectively. | |
The Company during the years ended December 31, 2014 and 2013 charged amortization expense of $1,593 and $10,000, respectively, which is included in the loss from discontinued operations. |
DUE_TO_FIRST_INSURANCE_FUNDING
DUE TO FIRST INSURANCE FUNDING | 12 Months Ended |
Dec. 31, 2014 | |
DUE TO FIRST INSURANCE FUNDING | |
DUE TO FIRST INSURANCE FUNDING | NOTE 9: DUE TO FIRST INSURANCE FUNDING |
The Company financed the purchase of its D & O insurance with a note due to First Insurance Funding. The principal amount financed was $120,000. Interest is due on the unpaid balance at a rate of 6.189% per annum. The total amount of interest due under the terms of the note is $3,116. The term of the note is nine months commencing August 25, 2014. Payments are due for nine installments in the amount of $13,680, which includes principal and interest, commencing August 25, 2014. |
COMMITMENT_AND_CONTINGENCIES
COMMITMENT AND CONTINGENCIES | 12 Months Ended |
Dec. 31, 2014 | |
COMMITMENT AND CONTINGENCIES | |
COMMITMENT AND CONTINGENCIES | NOTE 10: COMMITMENT AND CONTINGENCIES |
On June 13, 2014, the Company entered into an employment agreement with Dr. George Anastassov, its Chief Executive Officer, Chief Financial Officer and Secretary. The agreement’s effective date is June 1, 2014. The initial term of the agreement is one year. The agreement renews each year until terminated by the Company or Dr. Anastassov. Cash remuneration is $20,000 per month payable bi-monthly. Following 12 months of continuous employment the agreement calls for a 500,000 share restricted stock grant of the Company’s common shares, or at the sole option of the Company, its cash equivalent based on the ten day average closing price of the company’s common stock immediately preceding the grant date, as quoted on Yahoo Finance.com. Following 15 months of continuous employment and every three months thereafter the agreement calls for a 125,000 share restricted stock grant of the Company’s common shares, or at the sole option of the Company, its cash equivalent based on the ten day average closing price of the company’s common stock immediately preceding the grant date, as quoted on Yahoo Finance.com | |
On November 15, 2014 the Company and Municipality of Almere, the Netherlands entered into a “reservation agreement” whereas the Company is interested in the construction of a factory for the production of a new drug, on the plots of building and land located at Lagekant, the Netherlands. The reservation agreement is for a term of one year and expires on November 15, 2015. The Company must notify the Municipality of Almere whether or not it wishes to be considered for the purchase of the building and land on or before the end of the reservation agreement. If the municipality has not received notification on time before the end of the reservation period whether it wishes to purchase the building and land and also does not receive notification during the three (3) working days following said date, the right to reservation of the Company lapses. The municipality is then fully at liberty to offer the building land to any other prospective purchasers. The Company is entitled to terminate this agreement in writing without this giving rise to any payment obligation. The Company will incur a reservation fee after February 15, 2015 in the amount of 49,284 Euros. The purchase price has been determined to be 985,680 euro’s exclusive of VAT and transfer taxes. | |
ACCOUNTING_POLICIES_POLICIES
ACCOUNTING POLICIES (POLICIES) | 12 Months Ended |
Dec. 31, 2014 | |
ACCOUNTING POLICIES (POLICIES): | |
Use of Estimates, Policy | Use of estimates |
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenue and expenses during reporting periods. Actual results could differ from these estimates. | |
Cash Equivalents, Policy | Cash equivalents |
The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. | |
Revenue Recognition, Policy | Revenue Recognition |
The Company recognizes revenue on four basic criteria that must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the fee charged for services rendered and products delivered and the collectability of those fees. Revenue is generally recognized upon shipment. | |
Revenue recognized during the year ended December 31, 2014 and 2013 related to sales of product of $10,000 and $21,667, respectively, which is included in loss from discontinued operations. | |
Principles of consolidation | Principles of consolidation |
The consolidated financial statements include the accounts of Axim Biotechnologies, Inc. and its wholly owned subsidiary Axim Holdings, Inc. as of December 31, 2014. All significant intercompany transactions and balances have been eliminated in consolidation. | |
Fair Value of Financial Instruments, Policy | Fair value of financial instruments |
The Company follows paragraph 825-10-50-10 Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification ("Paragraph 820-10-35-37") to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value, and expands disclosures about fair value measurements | |
Income Taxes, Policy | Income taxes |
The Company follows Section 740-10, Income tax (“ASC 740-10”) Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date. | |
The Company adopted section 740-10-25 of the FASB Accounting Standards Codification ("Section 740-10-25"). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25. | |
Net loss per common share | Net loss per common share |
Net loss per common share is computed pursuant to section 260-10-45 Earnings Per Share (“ASC 260-10”) of the FASB Accounting Standards Codification. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be ant dilutive. | |
Recently issued accounting standards | Recently issued accounting standards |
In June of 2014 the Financial Accounting Standards Board issued Accounting Standards Update ASU 2014-10, “Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation” (“ASU 2014-10”). The amendments in ASU 2014-10 remove the definition of a development stage entity from the master glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. | |
In August, 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties About an Entities Ability to Continue as a Going Concern. The standard is intended to define management’s responsibility to decide whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The standard requires management to decide whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. The standard provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations in the footnotes. The standard becomes effective in the annual period ending after December 15, 2016, with early application permitted. The adoption of this pronouncement is not expected to have a material impact on the financial statements. Management’s evaluations regarding the events and conditions that raise substantial doubt regarding the Company’s ability to continue as a going concern have been disclosed in Note 7. | |
The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations. | |
The Company has elected to adopt the provisions of ASU 2014-10 for the current year ending December 31, 2014. The adoption of ASU 2014-10 did not have a significant impact on our results of operations, financial condition or cash flow. | |
Other recent accounting pronouncements issued by the FASB and the SEC did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements. |
CHANGE_OF_CONTROL_TABLES
CHANGE OF CONTROL (TABLES) | 12 Months Ended | |||
Dec. 31, 2014 | ||||
CHANGE OF CONTROL (TABLES) | ||||
CHANGE OF CONTROL (TABLES) | This was done with the consent of all creditors. | |||
Settlement of debt at point of sale: | Amount | |||
Accounts payable | $ | -54,389 | ||
Royalty payable | -2,750 | |||
Shareholder loan | -45,002 | |||
Allowance for doubtful accounts | -9,000 | |||
License fee receivable | 15,000 | |||
Paid in capital | $ | 96,141 |
PROMISSORY_NOTE_RELATED_PARTY_
PROMISSORY NOTE - RELATED PARTY (TABLES) | 12 Months Ended | ||||
Dec. 31, 2014 | |||||
PROMISSORY NOTE - RELATED PARTY (TABLES) | |||||
PROMISSORY NOTE - RELATED PARTY (TABLES) | The following table summarizes promissory note payable as of December 31, 2014 and 2013: | ||||
December 31, | December 31, | ||||
2014 | 2013 | ||||
Promissory note payable, due on demand, interest at 7% | $ | 1,000,000 | $ | - | |
Accrued interest | 28,053 | - | |||
$ | 1,028,053 | $ | - |
BASIS_OF_PRESENTATION_DETAILS
BASIS OF PRESENTATION (DETAILS) (USD $) | Jun. 09, 2014 |
Basis of presentation Details | |
Number of authorized shares of common stock of the Company before increase | 195,000,000 |
Number of authorized shares of common stock of the Company after increase | 300,000,000 |
Common stock, per share value | $0.00 |
REVENUE_DETAILS
REVENUE (DETAILS) (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Revenue | ||
Sales of product | $10,000 | $21,667 |
CHANGE_OF_CONTROL_DETAILS
CHANGE OF CONTROL (DETAILS) (USD $) | Dec. 31, 2014 | Mar. 21, 2014 |
Settlement of debt at point of sale: | ||
Accounts payable | ($54,389) | |
Royalty payable | -2,750 | |
Shareholder loan | -45,002 | |
Allowance for doubtful accounts | -9,000 | |
License fee receivable | 15,000 | |
Paid in capital | 96,141 | |
Convertible loan transferred and outstanding | $50,000 |
RELATED_PARTY_PROMISSORY_NOTE_
RELATED PARTY PROMISSORY NOTE (DETAILS) (USD $) | Dec. 31, 2014 | Aug. 08, 2014 | Dec. 31, 2013 |
Related party Promissory note | |||
Promissory note payable, due on demand, interest at 7% | $1,000,000 | $0 | |
Accrued interest on note | 28,053 | ||
Total amount of note payable | 1,028,053 | ||
CCB own outstanding shares of the Company | 90.00% | ||
Working capital fund | $1,000,000 | ||
Interest rate annually | 7.00% |
INTEREST_EXPENSE_DETAILS
INTEREST EXPENSE (DETAILS) (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Interest expense {1} | ||
Company recognized interest expense | $28,053 | $0 |
RELATED_PARTY_AGREEMENTS_DETAI
RELATED PARTY AGREEMENTS (DETAILS) (USD $) | Dec. 31, 2014 | Aug. 08, 2014 | Jun. 25, 2014 | 21-May-14 | Dec. 31, 2013 |
Related party agreements | |||||
Company president advanced to fund working capital needs | $45,002 | $5,000 | |||
Company entered into a separate Convertible Loan Agreement with its President and borrowed | 50,000 | ||||
The loan is convertible into common stock at a price per share | $0.10 | ||||
Total amount due to shareholder including convertible loan | 55,000 | ||||
Company entered into a Promissory Note Agreement with CanChew Biotechnologies, LLC and borrowed to fund working capital | 1,000,000 | ||||
Interest rate on note | 7.00% | ||||
Interest expense charged by the company in the period | 28,053 | ||||
Company received a non interest bearing advance from CCB | 30,000 | ||||
Advanced an additional operating expenses | 35,775 | ||||
Total outstanding due to related party | $65,775 | $0 |
GOING_CONCERN_DETAILS
GOING CONCERN (DETAILS) (USD $) | Dec. 31, 2014 |
GOING CONCERN DETAILS | |
Company has negative working capital | $580,723 |
Incurred accumulated deficit in the period | 691,964 |
Cash used in operating activities of continuing operations | $348,999 |
IMPAIRMENT_EXPENSES_OF_INTANGI
IMPAIRMENT EXPENSES OF INTANGIBLE ASSETS (DETAILS) (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Impairment expenses of Intangible assets | ||
Company charged as impairment expenses | $52,103 | $30,000 |
Company charged amortization expense | $1,593 | $10,000 |
FIRST_INSURANCE_FUNDING_DETAIL
FIRST INSURANCE FUNDING (DETAILS) (USD $) | Aug. 25, 2014 |
First Insurance Funding | |
The principle amount financed | $120,000 |
Interest due on the unpaid balance at a rate per annum | 6.19% |
The total amount of interest due under the terms of the note | 3,116 |
Payments are due for nine installments in the amount and includes principle and interest | $13,680 |
EMPLOYMENT_AGREEMENT_AND_COMMI
EMPLOYMENT AGREEMENT AND COMMITMENTS (DETAILS) (USD $) | Feb. 15, 2015 | Jun. 13, 2014 |
Employment agreement and commitments | ||
Cash remuneration in the amount per month payable bi-monthly | $20,000 | |
Restricted stock grant of the Company's common shares granted employment the agreement | 500,000 | |
Following 15 months of continuous employment and every three months thereafter the agreement Restricted stock granted | 125,000 | |
Reservation fee in euros | 49,284 | |
Purchase price exclusive of VAT and transfer taxes in euros | $985,680 |